Risuteganib for DED: Promising treatment with increased TBUT, low staining scores
July 25, 2021
Eric Donnenfeld, MD, highlights study results exhibiting risuteganib as a potential treatment option for dry eye disease.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Dry Eye
Treatment Options for Dry Eye Flares
July 27, 2021
Cynthia Matossian, MD, FACS, discusses the short- and long-term treatment options for dry eye flares.
Seeking Out Medical Care for Dry Eye Flares
July 20, 2021
Dr Matossian explains the importance of treating dry eye flares and what can happen if they are left unchecked.
Awareness of Dry Eye Flares
July 13, 2021
Dr Matossian elaborates on how both patients’ and physicians’ awareness of dry eyes flares affects their eyesight and how they move forward with treatment.
Dry Eye Flares: An Overview
June 30, 2021
Cynthia Matossian, MD, FACS, provides an overview on dry eye flares, including causes, symptoms, and her experience with dry eye flare patients.
Disparities in dry eye severity, access to dry eye care in racial and ethnic minorities
June 25, 2021
Patients who are members of racial and ethnic minority groups present clinically with worse objective measures of dry eye than patients who do not belong to these groups, new research shows.
Smartphone screening and referral increases access to care for people with eye problems
June 22, 2021
According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.
Oyster Point Pharma enrolls first subject in phase 2 clinical trial of OC-01 nasal spray for neurotrophic keratopathy
June 21, 2021
Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).
ASCRS 2021 going live
June 17, 2021
The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.
EyeGate Pharma announces first patient dosed in phase 2 ocular surface inflammation study
June 14, 2021
EyeGate Pharmaceuticals, Inc.'s lead product candidate is designed to treat dry eye disease-induced ocular surface inflammation.